Bradley C. Riemann, PhD (Clinical Director, OCD Center & CBT Services at Rogers Memorial Hospital) and Thröstur Björgvinsson, PhD (Program Director, Houston OCD Program) answered our questions.
Instead of letting her depression run her life, she decided to outrun it.
“I have clinical depression,” says Mara Suttman-Lea. “No, I am not depressed. I suffer from depression. They are two vastly different concepts.”
Our research team is conducting a study to learn more about the effects of a behavioral treatment program designed to improve positive emotions and behaviors and associated brain systems. We are seeking volunteers who experience feelings of anxiety or depression. The results of this study may help develop procedures to reduce symptoms of anxiety and depression, and improve positive emotions and well-being.
This study is testing to see what behavior and brain function can tell us about treatment success in depression using cognitive-behavioral therapy, a standard psychotherapy treatment for depressive disorders.
The study purpose is to evaluate what brain function can tell us about treatment success in anxiety disorders.
Time commitment is about 33 hours over 22 visits.
Volunteers will participate in the following:
18 to 25 years old
Suffering from depression
18 to 55 years old
Suffering from an anxiety disorder
Volunteers may not have metal in their body.
Are you or do you have a child or adolescent for whom anxiety is a concern? Do you consider yourself excessively nervous? Do you have fears about social or other situations?
The University of Illinois at Chicago is conducting a research study on child and adolescent anxiety. We are testing to see what genes, behavior, and brain function can tell us about successful treatment in child and adolescent anxiety using either talk therapy or a medication, both shown to be effective treatments. Participants will be randomized to receive either medication or therapy.
You may be eligible if
6 CE or CME
Ticketed event (includes lunch):
ADAA mourns the loss of Robin Williams and too many others whose lives have ended due to suicide. His tragic death illustrates the great need for increased public awareness of the grave risk that suicide poses.
The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. Individuals will receive 7 weeks of panic- and smoking-reduction treatment (PSRT) and one pill of d-cycloserine (DCS) or one pill placebo one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).